Patents by Inventor Shingo Miyamoto

Shingo Miyamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20120177649
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: February 3, 2012
    Publication date: July 12, 2012
    Applicant: KYOWA HAKKO KIRIN, CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • VIDEO SEARCH DEVICE, VIDEO SEARCH METHOD, RECORDING MEDIUM, PROGRAM, AND INTEGRATED CIRCUIT
    Publication number: 20120134648
    Abstract: A video search device extracts a plurality of objects each contained in a different one of frames of a video, assigns a weight value to each of the extracted objects based on a time-series feature of the frame containing the object, and searches for an object similar to each of the extracted objects based on the extracted objects each having the weight value assigned thereto.
    Type: Application
    Filed: March 17, 2011
    Publication date: May 31, 2012
    Inventors: Kouji Miura, Masaya Yamamoto, Shingo Miyamoto
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8173781
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 8, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8163282
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: April 24, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • DATA PROCESSING APPARATUS AND DATA PROCESSING METHOD
    Publication number: 20120020525
    Abstract: A data processing apparatus (10) is a data processing apparatus (10) that determines a target region within a picture contained in a video content, on the basis of a trajectory input by a user in order to surround a moving object in the video content, the data processing apparatus comprising: an input unit (11) configured to receive input data showing the trajectory input by the user in the displayed video content; and a correction unit (12) configured to correct an input region, which is a region specified by the trajectory expressed by the input data, to thereby determine the target region.
    Type: Application
    Filed: January 13, 2011
    Publication date: January 26, 2012
    Inventors: Shingo Miyamoto, Masaya Yamamoto, Kouji Miura, Minehisa Nagata
  • Anticancer Agent
    Publication number: 20110230418
    Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.
    Type: Application
    Filed: August 19, 2005
    Publication date: September 22, 2011
    Applicant: The Research Foundation For Microbial Diseases Of Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110052595
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: June 30, 2009
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Eisuke MEKADA, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110034673
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: October 30, 2009
    Publication date: February 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 7851601
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: December 14, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20100184958
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: December 8, 2008
    Publication date: July 22, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: EISUKE MEKADA, RYO IWAMOTO, SHINGO MIYAMOTO, KENYA SHITARA, AKIKO FURUYA, KAZUYASU NAKAMURA, KUMIKO TAKAHASHI, HIROSHI ANDO, KAZUHIRO MASUDA, YUKA SASAKI
  • Therapeutic agent for cancer
    Patent number: 7700546
    Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: April 20, 2010
    Assignee: The Research foundation for Microbial Diseases of Osaka c/o Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • Therapeutic Agent for Cancer
    Publication number: 20090105135
    Abstract: The present invention provides a cancer therapeutic agent containing as an active ingredient a substance, particularly CRM197 which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, wherein a cancer is selected from the group consisting of a bladder cancer, a colon cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
    Type: Application
    Filed: June 20, 2006
    Publication date: April 23, 2009
    Applicant: The Research Foundation for Microbail Diseases of Osaka University
    Inventors: Eisuke Mekada, Shingo Miyamoto
  • Anti-cancer agents
    Publication number: 20060270600
    Abstract: An anti-cancer agent comprising as an active component a protein which is a diphtheria toxin mutant such as CRM197, has an activity to inhibit binding of HB-EGF to an EGR receptor and substantially does not have toxicity of diphtheria toxin. The anti-cancer agent is particularly effective for the treatment of ovarian cancer, breast cancer and prostate cancer.
    Type: Application
    Filed: May 23, 2006
    Publication date: November 30, 2006
    Inventors: Eisuke Mekada, Shingo Miyamoto